Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness (Q39511808)

12 September 2017

Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness (English)

1 reference

cost-effectiveness analysis

12 September 2017

0 references

1 reference

Snyder DC

1

1 reference

12 September 2017

Paz EA

2

1 reference

12 September 2017

Mohle-Boetani JC

3

1 reference

12 September 2017

Fallstad R

4

1 reference

12 September 2017

Black RL

5

1 reference

12 September 2017

Chin DP

6

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

American Journal of Respiratory and Critical Care Medicine

12 September 2017

1 reference

12 September 2017

160

1 reference

12 September 2017

1

1 reference

12 September 2017

178-185

1 reference

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

12 September 2017

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Risk Factors for Tuberculosis in HIV-lnfected Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Accelerated course of human immunodeficiency virus infection after tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Progression of human immunodeficiency virus infection in patients with tuberculosis disease. A cohort study in Bordeaux, France, 1988-1994. The Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

The Markov process in medical prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

DNA fingerprinting with two probes decreases clustering of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Molecular approach to identifying route of transmission of tuberculosis in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.1.9810082

10.1164/AJRCCM.160.1.9810082

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference